Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Medtronic
Merck
Mallinckrodt
Express Scripts

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Grn163l

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Grn163l?

Grn163l is an investigational drug.

There have been 14 clinical trials for Grn163l. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, Plasma Cell, and Multiple Myeloma. The leading clinical trial sponsors are Geron Corporation, National Cancer Institute (NCI), and Janssen Research & Development, LLC.

There are eight US patents protecting this investigational drug and fifty-six international patents.

Recent Clinical Trials for Grn163l
TitleSponsorPhase
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)Phase 2
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid TumorsChildren's Oncology GroupPhase 2
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain TumorsNational Cancer Institute (NCI)Phase 2

See all Grn163l clinical trials

Clinical Trial Summary for Grn163l

Top disease conditions for Grn163l
Top clinical trial sponsors for Grn163l

See all Grn163l clinical trials

US Patents for Grn163l

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Grn163l   Start Trial Method for identification of sensitivity of a patient to telomerase inhibition therapy Geron Corporation (Menlo Park, CA)   Start Trial
Grn163l   Start Trial Combined telomerase inhibitor and gemcitabine for the treatment of cancer Geron Corporation (Menlo Park, CA)   Start Trial
Grn163l   Start Trial Cancer treatment by combined inhibition of proteasome and telomerase activities Geron Corporation (Menlo Park, CA) Memorial Sloan-Kettering Cancer Center (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
AstraZeneca
Harvard Business School
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.